Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study

被引：0
|
作者：
Siegel, D. S. [1 ,2 ,3 ,4 ,5 ,6 ]
Weber, D. M. [1 ,2 ,3 ,4 ,5 ,6 ]
Mitsiades, C. S. [1 ,2 ,3 ,4 ,5 ,6 ]
Dimopoulos, M. A. [1 ,2 ,3 ,4 ,5 ,6 ]
Harousseau, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
Rizvi, S. [1 ,2 ,3 ,4 ,5 ,6 ]
Howe, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Reiser, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Anderson, K. C. [1 ,2 ,3 ,4 ,5 ,6 ]
Richardson, P. G. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Athens, Sch Med, GR-11527 Athens, Greece
[5] Ctr Rene Gauducheau, Saint Herblain, France
[6] Merck & Co Inc, Upper Gwynedd, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8586
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [32] A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens
    Sanchez, Larysa
    Vesole, David H.
    Richter, Joshua R.
    Biran, Noa
    Bilotti, Elizabeth
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 440 - 447
  • [33] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
  • [34] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
    Lonial, S.
    Vij, R.
    Harousseau, J.
    Facon, T.
    Moreau, P.
    Leleu, X.
    Westland, C.
    Singhal, A. K.
    Jagannath, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [36] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
    Waldschmidt, Johannes M.
    Keller, Alexander
    Ihorst, Gabriele
    Grishina, Olga
    Mueller, Stefan
    Wider, Dagmar
    Frey, Anna V.
    King, Kristina
    Simon, Roman
    May, Annette
    Tassone, Pierfrancesco
    Duyster, Justus
    Jung, Manfred
    Raje, Noopur
    Waesch, Ralph
    Engelhardt, Monika
    HAEMATOLOGICA, 2018, 103 (10) : E473 - E479
  • [38] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [39] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [40] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
12345